Full Text Journal Articles by
Author Stefan Agewall

Advertisement

Find full text journal articles






Comparative efficacy of sodium-glucose cotransporter-2 inhibitors (SGLT2i) for cardiovascular outcomes in type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials.

Tobias Täger, Dan Atar, Stefan Agewall, Hugo A Katus, Morten Grundtvig, John G F Cleland, Andrew L Clark, Hanna Fröhlich, Lutz Frankenstein,

Sodium-glucose cotransporter-2 inhibitors (SGLT2i) improve cardiovascular outcomes in patients with type 2 diabetes mellitus (T2D). The comparative efficacy of individual SGLT2i remains unclear. We searched PubMed, www.clinicaltrials.gov and the Cochrane Central Register of Controlled Trials for randomised controlled trials exploring the use of canagliflozin, dapagliflozin, empagliflozin or ertugliflozin in patients ... Read more >>

Heart Fail Rev (Heart failure reviews)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Antithrombotic therapy and major adverse limb events in patients with chronic lower extremity arterial disease: systematic review and meta-analysis from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy in Collaboration with the European Society of Cardiology Working Group on Aorta and Peripheral Vascular Diseases.

Gianluigi Savarese, Martin F Reiner, Alicia Uijl, Domenico D'Amario, Stefan Agewall, Dan Atar, Iris Baumgartner, Claudio Borghi, Marco De Carlo, Heinz Drexel, Juan Carlos Kaski, Keld P Kjeldsen, Nils Kucher, Lars H Lund, Alexander Niessner, Anne Grete Semb, Thomas A Schmidt, Patrick Sulzgruber, Juan Tamargo, Cristiana Vitale, Sven Wassmann, Victor Aboyans, Basil S Lewis,

AIMS:The role and selection of antithrombotic therapy to improve limb outcomes in chronic lower extremity artery disease (LEAD) is still debated. We conducted a meta-analysis to examine the efficacy and safety of antithrombotic and more intense antithrombotic therapy on limb outcomes and limb salvage in patients with chronic LEAD. METHODS ... Read more >>

Eur Heart J Cardiovasc Pharmacother (European heart journal. Cardiovascular pharmacotherapy)
[2020, 6(2):86-93]

Cited: 1 time

View full text PDF listing >>



Advertisement

The age of randomized clinical trials: three important aspects of randomized clinical trials in cardiovascular pharmacotherapy with examples from lipid and diabetes trials.

Heinz Drexel, Giuseppe M C Rosano, Basil S Lewis, Kurt Huber, Alexander Vonbank, Jörn F Dopheide, Arthur Mader, Alexander Niessner, Gianluigi Savarese, Sven Wassmann, Stefan Agewall,

Randomized clinical trials (RCTs) are important and the Gold Standard for drugs in modern cardiovascular (CV) therapy. The cornerstone of RCTs is the recording of hard clinical endpoints instead of surrogates. It is important to select an appropriate endpoint. Efficacy endpoints must be clinically relevant and can be hierarchically divided. ... Read more >>

Eur Heart J Cardiovasc Pharmacother (European heart journal. Cardiovascular pharmacotherapy)
[2020, 6(2):97-103]

Cited: 0 times

View full text PDF listing >>



Lipid management in rheumatoid arthritis: a position paper of the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology.

Ivana Hollan, Nicoletta Ronda, Patrick Dessein, Stefan Agewall, George Karpouzas, Juan Tamargo, Alexander Niessner, Gianluigi Savarese, Giuseppe Rosano, Juan Carlos Kaski, Sven Wassmann, Pier Luigi Meroni,

Rheumatoid arthritis (RA) is associated with increased cardiovascular morbidity, partly due to alterations in lipoprotein quantity, quality and cell cholesterol trafficking. Although cardiovascular disease significantly contributes to mortality excess in RA, cardiovascular prevention has been largely insufficient. Because of limited evidence, optimal strategies for lipid management (LM) in RA have ... Read more >>

Eur Heart J Cardiovasc Pharmacother (European heart journal. Cardiovascular pharmacotherapy)
[2020, 6(2):104-114]

Cited: 0 times

View full text PDF listing >>



2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes.

Juhani Knuuti, William Wijns, Antti Saraste, Davide Capodanno, Emanuele Barbato, Christian Funck-Brentano, Eva Prescott, Robert F Storey, Christi Deaton, Thomas Cuisset, Stefan Agewall, Kenneth Dickstein, Thor Edvardsen, Javier Escaned, Bernard J Gersh, Pavel Svitil, Martine Gilard, David Hasdai, Robert Hatala, Felix Mahfoud, Josep Masip, Claudio Muneretto, Marco Valgimigli, Stephan Achenbach, Jeroen J Bax, ,

Eur. Heart J. (European heart journal)
[2020, 41(3):407-477]

Cited: 4 times

View full text PDF listing >>



2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS).

Stavros V Konstantinides, Guy Meyer, Cecilia Becattini, Héctor Bueno, Geert-Jan Geersing, Veli-Pekka Harjola, Menno V Huisman, Marc Humbert, Catriona Sian Jennings, David Jiménez, Nils Kucher, Irene Marthe Lang, Mareike Lankeit, Roberto Lorusso, Lucia Mazzolai, Nicolas Meneveau, Fionnuala Ní Áinle, Paolo Prandoni, Piotr Pruszczyk, Marc Righini, Adam Torbicki, Eric Van Belle, José Luis Zamorano, ,

Eur. Heart J. (European heart journal)
[2020, 41(4):543-603]

Cited: 1 time

View full text PDF listing >>



Focus on pharma in acute coronary syndrome.

Stefan Agewall,

Eur Heart J Cardiovasc Pharmacother (European heart journal. Cardiovascular pharmacotherapy)
[2020, 6(1):1-2]

Cited: 0 times

View full text PDF listing >>



All-Cause Mortality and Cardiovascular Outcomes With Non-Vitamin K Oral Anticoagulants Versus Warfarin in Patients With Heart Failure in the Food and Drug Administration Adverse Event Reporting System.

Thomas G von Lueder, Dan Atar, Stefan Agewall, Jesper K Jensen, Ingrid Hopper, Dipak Kotecha, Robert J Mentz, Moo Hyun Kim, Victor L Serebruany,

BACKGROUND:Many patients with heart failure (HF) are treated with warfarin or non-vitamin K oral anticoagulants (NOACs). Randomized outcome-driven comparisons of different anticoagulant strategies in HF are lacking. Data from international, government-mandated registries may be useful in understanding the real-life use of various anticoagulants and how they are linked to outcomes. ... Read more >>

Am J Ther (American journal of therapeutics)
[2019, 26(6):e671-e678]

Cited: 0 times

View full text PDF listing >>



Hyperkalemia and Renin-Angiotensin-Aldosterone System Inhibitors Dose Therapy in Heart Failure With Reduced Ejection Fraction.

Giuseppe Mc Rosano, Ilaria Spoletini, Cristiana Vitale, Stefan Agewall,

Renin-angiotensin-aldosterone system inhibitors (RAASi) are known to improve outcomes in patients who have heart failure with reduced ejection fraction (HFrEF). To reduce mortality in these patients, RAASi should be uptitrated to the maximally tolerated dose. However, RAASi may also cause hyperkalemia. As a result of this side-effect, doses of RAASi ... Read more >>

Card Fail Rev (Cardiac failure review)
[2019, 5(3):130-132]

Cited: 0 times

View full text PDF listing >>



Progression of conventional cardiovascular risk factors and vascular disease risk in individuals: insights from the PROG-IMT consortium.

Martin Bahls, Matthias W Lorenz, Marcus Dörr, Lu Gao, Kazuo Kitagawa, Tomi-Pekka Tuomainen, Stefan Agewall, Gerald Berenson, Alberico L Catapano, Giuseppe D Norata, Michiel L Bots, Wiek van Gilst, Folkert W Asselbergs, Frank P Brouwers, Heiko Uthoff, Dirk Sander, Holger Poppert, Michael Hecht Olsen, Jean Philippe Empana, Ulf Schminke, Damiano Baldassarre, Fabrizio Veglia, Oscar H Franco, Maryam Kavousi, Eric de Groot, Ellisiv B Mathiesen, Liliana Grigore, Joseph F Polak, Tatjana Rundek, Coen DA Stehouwer, Michael R Skilton, Apostolos I Hatzitolios, Christos Savopoulos, George Ntaios, Matthieu Plichart, Stela McLachlan, Lars Lind, Peter Willeit, Helmuth Steinmetz, Moise Desvarieux, M Arfan Ikram, Stein Harald Johnsen, Caroline Schmidt, Johann Willeit, Pierre Ducimetiere, Jackie F Price, Göran Bergström, Jussi Kauhanen, Stefan Kiechl, Matthias Sitzer, Horst Bickel, Ralph L Sacco, Albert Hofman, Henry Völzke, Simon G Thompson, ,

AIMS:Averaged measurements, but not the progression based on multiple assessments of carotid intima-media thickness, (cIMT) are predictive of cardiovascular disease (CVD) events in individuals. Whether this is true for conventional risk factors is unclear. METHODS AND RESULTS:An individual participant meta-analysis was used to associate the annualised progression of systolic blood ... Read more >>

Eur J Prev Cardiol (European journal of preventive cardiology)
[2020, 27(3):234-243]

Cited: 0 times

View full text PDF listing >>



European Heart Journal - Cardiovascular Pharmacotherapy has received its first Impact Factor of 6.723.

Stefan Agewall,

Eur Heart J Cardiovasc Pharmacother (European heart journal. Cardiovascular pharmacotherapy)
[2019, 5(4):183-184]

Cited: 0 times

View full text PDF listing >>



Mortality and adverse events with brand and generic clopidogrel in the US Food and Drug Administration Adverse Event Reporting System.

Victor L Serebruany, Trygve S Hall, Dan Atar, Stefan Agewall, Moo Hyun Kim, Bernard Geudelin, Nikita Lomakin, Thomas A Marciniak,

AIMS:Clopidogrel is commonly used even after expiring patents. The brand clopidogrel (BC) was dealt by single company, while numerous manufacturers produce generic clopidogrel (GC). There are no convincing data to compare the safety of different formulations. Therefore, the data yielded from international, uniform, government-mandated registries may be useful. METHODS AND ... Read more >>

Eur Heart J Cardiovasc Pharmacother (European heart journal. Cardiovascular pharmacotherapy)
[2019, 5(4):210-215]

Cited: 0 times

View full text PDF listing >>



2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC).

Stavros V Konstantinides, Guy Meyer, Cecilia Becattini, Héctor Bueno, Geert-Jan Geersing, Veli-Pekka Harjola, Menno V Huisman, Marc Humbert, Catriona Sian Jennings, David Jiménez, Nils Kucher, Irene Marthe Lang, Mareike Lankeit, Roberto Lorusso, Lucia Mazzolai, Nicolas Meneveau, Fionnuala Ní Áinle, Paolo Prandoni, Piotr Pruszczyk, Marc Righini, Adam Torbicki, Eric Van Belle, José Luis Zamorano, ,

Eur. Respir. J. (The European respiratory journal)
[2019, 54(3):]

Cited: 1 time

View full text PDF listing >>



Oral Anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1.

Patrick Sulzgruber, Sven Wassmann, Anne Grete Semb, Wolfram Doehner, Petr Widimsky, Thomas Gremmel, Juan Carlos Kaski, Gianluigi Savarese, Giuseppe M C Rosano, Claudio Borghi, Keld Kjeldsen, Christian Torp-Pedersen, Thomas Andersen Schmidt, Basil S Lewis, Heinz Drexel, Juan Tamargo, Dan Atar, Stefan Agewall, Alexander Niessner,

Eur. Heart J. (European heart journal)
[2019, 40(36):3010-3012]

Cited: 0 times

View full text PDF listing >>



Tumor necrosis factor inhibitors are associated with reduced complement activation in spondylarthropathies: An observational study.

Ingrid Hokstad, Gia Deyab, Morten Wang Fagerland, Torstein Lyberg, Gunnbjørg Hjeltnes, Øystein Førre, Stefan Agewall, Tom Eirik Mollnes, Ivana Hollan,

BACKGROUND:The complement system is involved in pathogenesis of cardiovascular disease, and might play a role in accelerated atherogenesis in spondylarthropathies (SpA). Hence, we examined complement activation in SpA, and its relationship to antirheumatic treatment, inflammatory and cardiovascular markers. METHODS:From PSARA, a prospective observational study, we examined 51 SpA patients (31 ... Read more >>

PLoS ONE (PloS one)
[2019, 14(7):e0220079]

Cited: 1 time

View full text PDF listing >>



Antiplatelet treatment in acute coronary syndrome. Still an issue.

Stefan Agewall,

Eur Heart J Cardiovasc Pharmacother (European heart journal. Cardiovascular pharmacotherapy)
[2019, 5(3):125-126]

Cited: 0 times

View full text PDF listing >>



Oral anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1: a current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on Stroke.

Patrick Sulzgruber, Sven Wassmann, Anne Grete Semb, Wolfram Doehner, Petr Widimsky, Thomas Gremmel, Juan Carlos Kaski, Gianluigi Savarese, Giuseppe M C Rosano, Claudio Borghi, Keld Kjeldsen, Christian Torp-Pedersen, Thomas Andersen Schmidt, Basil S Lewis, Heinz Drexel, Juan Tamargo, Dan Atar, Stefan Agewall, Alexander Niessner,

Oral anticoagulation in patients presenting with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1 (CHA2DS2-VASc of 2 in women) remains a challenging approach in clinical practice. Therapeutic decisions need to balance the individual benefit of reducing thromboembolic risk against the potential harm due to an increase in bleeding risk ... Read more >>

Eur Heart J Cardiovasc Pharmacother (European heart journal. Cardiovascular pharmacotherapy)
[2019, 5(3):171-180]

Cited: 0 times

View full text PDF listing >>



Left ventricular ejection fraction and adjudicated, cause-specific hospitalizations after myocardial infarction complicated by heart failure or left ventricular dysfunction.

Trygve S Hall, Thomas G von Lueder, Faiez Zannad, Patrick Rossignol, Kevin Duarte, Tahar Chouihed, Scott D Solomon, Kenneth Dickstein, Dan Atar, Stefan Agewall, Nicolas Girerd, ,

BACKGROUND:Reduced left ventricular ejection fraction (LVEF) after acute myocardial infarction (MI) increases risk of cardiovascular (CV) hospitalizations, but evidence regarding its association with non-CV outcome is scarce. We investigated the association between LVEF and adjudicated cause-specific hospitalizations following MI complicated with low LVEF or overt heart failure (HF). METHODS:In an ... Read more >>

Am. Heart J. (American heart journal)
[2019, 215:83-90]

Cited: 0 times

View full text PDF listing >>



Medical misinformation: vet the message!

Joseph A Hill, ,

J Interv Card Electrophysiol (Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing)
[2019, 55(1):1-3]

Cited: 0 times

View full text PDF listing >>



Increased Inflammatory Activity in Patients 3 Months after Myocardial Infarction with Nonobstructive Coronary Arteries.

Marcus Hjort, Kai M Eggers, Lars Lindhagen, Stefan Agewall, Elin B Brolin, Olov Collste, Maria Daniel, Christina Ekenbäck, Mats Frick, Loghman Henareh, Claes Hofman-Bang, Karin Malmqvist, Jonas Spaak, Peder Sörensson, Shams Y-Hassan, Per Tornvall, Bertil Lindahl,

BACKGROUND:Around 5%-10% of patients with myocardial infarction (MI) present with nonobstructive coronary arteries (MINOCA). We aimed to assess pathophysiological mechanisms in MINOCA by extensively evaluating cardiovascular biomarkers in the stable phase after an event, comparing MINOCA patients with cardiovascular healthy controls and MI patients with obstructive coronary artery disease (MI-CAD). ... Read more >>

Clin. Chem. (Clinical chemistry)
[2019, 65(8):1023-1030]

Cited: 0 times

View full text PDF listing >>



European Heart Journal - Cardiovascular Pharmacotherapy: now accepted for an official Impact Factor.

Stefan Agewall,

Eur Heart J Cardiovasc Pharmacother (European heart journal. Cardiovascular pharmacotherapy)
[2019, 5(2):59]

Cited: 0 times

View full text PDF listing >>



ST-segment elevation and cardiac magnetic resonance imaging findings in myocardial infarction with non-obstructive coronary arteries.

Anais Hausvater, Sivabaskari Pasupathy, Per Tornvall, Himali Gandhi, Rosanna Tavella, John Beltrame, Stefan Agewall, Christina Ekenbäck, Elin Bacsovics Brolin, Judith S Hochman, Olov Collste, Harmony R Reynolds,

PURPOSE:Patients with myocardial infarction and non-obstructive coronary arteries (MINOCA) may present with or without ST-elevation (STE) on the electrocardiogram (ECG). Previous studies have shown that STE was associated with higher risk of early mortality and long-term major adverse coronary events, and that cardiac magnetic resonance imaging (CMR) can help to ... Read more >>

Int. J. Cardiol. (International journal of cardiology)
[2019, 287:128-131]

Cited: 0 times

View full text PDF listing >>



Medical misinformation: vet the message!

Joseph A Hill, Stefan Agewall, Adrian Baranchuk, George W Booz, Jeffrey S Borer, Paolo G Camici, Peng-Sheng Chen, Anna F Dominiczak, Çetin Erol, Cindy L Grines, Robert Gropler, Tomasz J Guzik, Markus K Heinemann, Ami E Iskandrian, Bradley P Knight, Barry London, Thomas F Lüscher, Marco Metra, Kiran Musunuru, Brahmajee K Nallamothu, Andrea Natale, Sanjeev Saksena, Michael H Picard, Sunil V Rao, Willem J Remme, Robert S Rosenson, Nancy K Sweitzer, Adam Timmis, Christiaan Vrints,

Eur Heart J Cardiovasc Pharmacother (European heart journal. Cardiovascular pharmacotherapy)
[2019, 5(2):62-63]

Cited: 0 times

View full text PDF listing >>



Contemporary Diagnosis and Management of Patients With Myocardial Infarction in the Absence of Obstructive Coronary Artery Disease: A Scientific Statement From the American Heart Association.

Jacqueline E Tamis-Holland, Hani Jneid, Harmony R Reynolds, Stefan Agewall, Emmanouil S Brilakis, Todd M Brown, Amir Lerman, Mary Cushman, Dharam J Kumbhani, Cynthia Arslanian-Engoren, Ann F Bolger, John F Beltrame, ,

Myocardial infarction in the absence of obstructive coronary artery disease is found in ≈5% to 6% of all patients with acute infarction who are referred for coronary angiography. There are a variety of causes that can result in this clinical condition. As such, it is important that patients are appropriately ... Read more >>

Circulation (Circulation)
[2019, 139(18):e891-e908]

Cited: 4 times

View full text PDF listing >>



Unsolved issues in oral anticoagulation treatment in atrial fibrillation.

Stefan Agewall,

Eur Heart J Cardiovasc Pharmacother (European heart journal. Cardiovascular pharmacotherapy)
[2019, 5(2):60-61]

Cited: 0 times

View full text PDF listing >>



Advertisement

Disclaimer
1.1357 s